spacer spacer

spacer

Torsten Nielsen

  • B.Sc. (UBC 91)
  • Ph.D. (McGill 96)
  • M.D.,C.M. (McGill 97)
Professor, Departments of Pathology (Full Professor since 2012, Associate Professor since 2007) and of Orthopaedics (since 2005)

website: http://members.shaw.ca/tonielsen/

TRAINING EXPERIENCES
Anatomical Pathology residency (UBC)
additional training at: Imperial Cancer Research Fund (London UK), Stanford University, PhenoPath laboratories (Seattle), University of Washington, Cleveland Clinic Foundation, Royal Orthopaedic Hospital

GPEC RESPONSIBILITIES
Directing research in sarcoma and breast cancer; applying expression profiling data

RESEARCH INTERESTS
Tissue microarrays, cDNA microarrays, sarcoma, breast cancer, predictive biomarkers, molecular oncology, experimental therapeutics

PROJECTS Please see link.

AWARDS AND DISTINCTIONS
  • Associate Director, MD/PhD program, University of British Columbia (2007)
  • Senior Scholar of the Michael Smith Foundation for Health Research (2008)
  • Canadian Association of Pathologists: Junior Scientist Award (2005)
  • Canadian Institutes of Health Research: New Investigator Award (2004)
  • United States & Canadian Academy of Pathology: Stowell-Orbison Award (2001)
  • Royal College of Physicians & Surgeons of Canada: KJR Wightman Award for Research in Medical Ethics (1998)

PUBLICATIONS
Please also see link.

  • Nielsen TO. Discovery research to clinical trial: A ten year journey. Clin Invest Med. 33(6):E342 (2010).

  • Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielsen TO. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor. Sarcoma. 2010.

  • Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 16(21):5222-32 (2010).

  • Su L, Cheng H, Sampaio AV, Nielsen TO, Underhill TM. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene. 29(30):4352-61 (2010).

  • Pacheco M, Horsman DE, Hayes MM, Clarkson PW, Huwait H, Nielsen TO.Small blue round cell tumor of the interosseous membrane bearing a t(2;22)(q34;q12)/EWS-CREB1 translocation: a case report. Mol Cytogenet. 3:12 (2010).

  • Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7(5):e1000279 (2010).

  • Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28(20):3271-7 (2010)

  • Nielsen TO, West RB. Translating gene expression into clinical care: sarcomas as a paradigm. J Clin Oncol. 28(10):1796-805 (2010).

  • Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 28(10):1684-91 (2010)

  • Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 119(1):53-61 (2010).

  • Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 27(8):1160-7 (2009).

  • Liu S, Cheng H, Kwan W, Lubieniecka JM, Nielsen TO. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther. 7(6):1751-61 (2008).

  • Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG, Nielsen TO. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res. 68(11):4303-10 (2008).

  • Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 14(5):1368-76 (2008).

  • Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol. 18(2):89-97 (2008).

  • Cheang MC, van de Rijn M, Nielsen TO. Gene expression profiling of breast cancer. Annu Rev Pathol. 3:67-97 (2008).

  • Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, Corless CL, Fire AZ, van de Rijn M. MicroRNA expression signature of human sarcomas. Oncogene. 27(14):2015-26 (2008).

  • Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Loberg EM, Isaksen V, Eide TJ, Nielsen TO. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol. 21(1):46-53 (2008).

  • Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 8(6):513-24 (2007)

  • Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M, Nielsen TO. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. American Journal of Surgical Pathology. 31(2):240-246 (2007).

  • Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown AM. Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. J Clin Oncol. 24(36):5637-5644 (2006).

  • Nielsen TO. Microarray analysis of sarcomas. Advances in Anatomic Pathology. 13(4):166-173 (2006).

  • West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.Proc Natl Acad Sci U S A. 103(3):690-5 (2006).

  • Moyano JV, Evans J, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL. alpha-Beta-Crystallin: A novel oncoprotein that predicts poor clinical outcome in breast cancer. Journal of Clinical Investigation. 116(1):261-70 (2005).

  • Terry J, Lubieniecka JM, Kwan W, Liu S, Nielsen TO. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clinical Cancer Research. 11:5631-8 (2005).

  • Terry J, Barry TS, Hsu FD, Horsman D, Huntsman DG, Gown AM, Nielsen TO. Fluorescence in situ hybridization for the detection of t(x;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray. Diagnostic Molecular Pathology. 14:77-82 (2005).

  • West RB, Nuyten DSA, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M. Determination of stromal signatures in breast carcinoma. PLoS Biology. 3(6):e187 (2005).

  • Ng TL, Gown AM, Barry TS, Hsu FD, Cheang MCU, Chan A, Turbin D, West RB, Nielsen TO. Nuclear beta-catenin expression in sarcomas. Modern Pathology. 18(1):68-74 (2005).

  • Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hernandez-Boussard T, Cowan D, Dressler L, Livasy C, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research. 10(16):5367-74 (2004).

last updated 2010-12-15
Principal Investigators
  • C. Blake Gilks
  • David Huntsman
  • Torsten Nielsen
  • Team
  • Christine Chow
  • Dave Voduc
  • Dongxia (Doris) Gao
  • Jennifer Choo
  • Niki Boyd
  • Samuel Leung
  • Sherman Lau
  • Alumni
  • Alessandro DeLuca
  • Andy Chan
  • Ashish Rajput
  • Blaise Clarke
  • Challayne Smith
  • Cindy Ruttan
  • Diana Ionescu
  • Dmitry Turbin
  • Dustin Thomson
  • Edward Lee
  • Erika Mehl
  • Erika Yorida
  • Hamid Masoudi
  • Jen Born
  • Jenny Cromarty
  • Jon Carrick
  • Krista Marcon
  • Maggie Cheang
  • Martin Koebel
  • Melinda Miller
  • Nicholas Au
  • Nikita Makretsov
  • Sonja Steigen
  • Steve Kalloger
  • Vlady Pavlova
  • spacer
    spacer
    spacer
    Logo
    spacer
    spacer
    Copyright © 2014 Genetic Pathology Evaluation Centre All Rights Reserved; Last modified March 28, 2014